Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST).
Fiche du document
3 février 2017
- doi: 10.1186/s12902-017-0156-8
- issn: 1472-6823
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12902-017-0156-8
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/28158982
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1472-6823
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_428A147041FF0
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
TherapyCiter ce document
D.J. Stott et al., « Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST). », Serveur académique Lausannois, ID : 10.1186/s12902-017-0156-8
Métriques
Partage / Export
Résumé
Subclinical hypothyroidism (SCH) is a common condition in elderly people, defined as elevated serum thyroid-stimulating hormone (TSH) with normal circulating free thyroxine (fT4). Evidence is lacking about the effect of thyroid hormone treatment. We describe the protocol of a large randomised controlled trial (RCT) of Levothyroxine treatment for SCH. Participants are community-dwelling subjects aged ≥65 years with SCH, diagnosed by elevated TSH levels (≥4.6 and ≤19.9 mU/L) on a minimum of two measures ≥ three months apart, with fT4 levels within laboratory reference range. The study is a randomised double-blind placebo-controlled parallel group trial, starting with levothyroxine 50 micrograms daily (25 micrograms in subjects